Literature DB >> 24161413

Coverage and cost of a large oral cholera vaccination program in a high-risk cholera endemic urban population in Dhaka, Bangladesh.

Iqbal Ansary Khan1, Amit Saha, Fahima Chowdhury, Ashraful Islam Khan, Md Jasim Uddin, Yasmin A Begum, Baizid Khoorshid Riaz, Sanjida Islam, Mohammad Ali, Stephen P Luby, John D Clemens, Alejandro Cravioto, Firdausi Qadri.   

Abstract

A feasibility study of an oral cholera vaccine was carried out to test strategies to reach high-risk populations in urban Mirpur, Dhaka, Bangladesh. The study was cluster randomized, with three arms: vaccine, vaccine plus safe water and hand washing practice, and no intervention. High risk people of age one year and above (except pregnant woman) from the two intervention arms received two doses of the oral cholera vaccine, Shanchol™. Vaccination was conducted between 17th February and 16th April 2011, with a minimum interval of fourteen days between two doses. Interpersonal communication preceded vaccination to raise awareness amongst the target population. The number of vaccine doses used, the population vaccinated, left-out, drop out, vaccine wastage and resources required were documented. Fixed outreach site vaccination strategy was adopted as the mode of vaccine delivery. Additionally, mobile vaccination sites and mop-up activities were carried out to reach the target communities. Of the 172,754 target population, 141,839 (82%) and 123,666 (72%) received complete first and second doses of the vaccine, respectively. Dropout rate from the first to the second dose was 13%. Two complete doses were received by 123,661 participants. Vaccine coverage in children was 81%. Coverage was significantly higher in females than in males (77% vs. 66%, P<0.001). Vaccine wastage for delivering the complete doses was 1.2%. The government provided cold-chain related support at no cost to the project. Costs for two doses of vaccine per-person were US$3.93, of which US$1.63 was spent on delivery. Cost for delivering a single dose was US$0.76. We observed no serious adverse events. Mass vaccination with oral cholera vaccine is feasible for reaching high risk endemic population through the existing national immunization delivery system employed by the government.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bangladesh; Cholera vaccine; Complete dose; Endemic high risk targeted population; Feasibility

Mesh:

Substances:

Year:  2013        PMID: 24161413     DOI: 10.1016/j.vaccine.2013.10.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  37 in total

1.  Climate-driven endemic cholera is modulated by human mobility in a megacity.

Authors:  Javier Perez-Saez; Aaron A King; Andrea Rinaldo; Mohammad Yunus; Abu S G Faruque; Mercedes Pascual
Journal:  Adv Water Resour       Date:  2016-11-27       Impact factor: 4.510

Review 2.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 3.  Killed oral cholera vaccines: history, development and implementation challenges.

Authors:  Anna Lena Lopez; Maria Liza Antoinette Gonzales; Josephine G Aldaba; G Balakrish Nair
Journal:  Ther Adv Vaccines       Date:  2014-09

Review 4.  Maximizing protection from use of oral cholera vaccines in developing country settings: an immunological review of oral cholera vaccines.

Authors:  Sachin N Desai; Alejandro Cravioto; Dipika Sur; Suman Kanungo
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 5.  Systematic review of the incremental costs of interventions that increase immunization coverage.

Authors:  Sachiko Ozawa; Tatenda T Yemeke; Kimberly M Thompson
Journal:  Vaccine       Date:  2018-05-10       Impact factor: 3.641

6.  Geographical diversity in seasonality of major diarrhoeal pathogens in Bangladesh observed between 2010 and 2012.

Authors:  S K Das; D Begum; S Ahmed; F Ferdous; F D Farzana; M J Chisti; J R Latham; K A Talukder; M M Rahman; Y A Begum; A S G Faruque; M A Malek; F Qadri; T Ahmed; N Alam
Journal:  Epidemiol Infect       Date:  2014-02-13       Impact factor: 4.434

7.  Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 2013.

Authors:  Rania A Tohme; Jeannot François; Kathleen Wannemuehler; Preetha Iyengar; Amber Dismer; Paul Adrien; Terri B Hyde; Barbara J Marston; Kashmira Date; Eric Mintz; Mark A Katz
Journal:  Emerg Infect Dis       Date:  2015-06       Impact factor: 6.883

8.  An Estimation of Private Household Costs to Receive Free Oral Cholera Vaccine in Odisha, India.

Authors:  Vittal Mogasale; Shantanu K Kar; Jong-Hoon Kim; Vijayalaxmi V Mogasale; Anna S Kerketta; Bikash Patnaik; Shyam Bandhu Rath; Mahesh K Puri; Young Ae You; Hemant K Khuntia; Brian Maskery; Thomas F Wierzba; Binod Sah
Journal:  PLoS Negl Trop Dis       Date:  2015-09-09

9.  A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia.

Authors:  Sachin N Desai; Zenebe Akalu; Samuel Teshome; Mekonnen Teferi; Lawrence Yamuah; Deok Ryun Kim; Jae Seung Yang; Jemal Hussein; Ju Yeong Park; Mi Seon Jang; Chalachew Mesganaw; Hawult Taye; Demissew Beyene; Ahmed Bedru; Ajit Pal Singh; Thomas F Wierzba; Abraham Aseffa
Journal:  Am J Trop Med Hyg       Date:  2015-06-15       Impact factor: 2.345

10.  Cost of vaccine delivery strategies in low- and middle-income countries during the COVID-19 pandemic.

Authors:  Christina Banks; Allison Portnoy; Flavia Moi; Laura Boonstoppel; Logan Brenzel; Stephen C Resch
Journal:  Vaccine       Date:  2021-06-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.